China NT Pharma Group Company Limited provided consolidated earnings guidance for the six months ended June 30, 2014. The Group is expected to record a net result around the breakeven region for the six months ended 30 June 2014, representing a substantial improvement of the results of the Group as compared to the net loss of approximately RMB 432 million for the corresponding period in 2013, mainly because no material restructuring cost is anticipated to be incurred for the six months ended 30 June 2014, as compared with total restructuring costs of approximately RMB 329 million for the corresponding period in 2013.